Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Small cell lung cancer (SCLC) is an aggressive disease with one of the highest case-fatality rates among cancer. The recommended therapy for SCLCs has not changed significantly over the past 30 years; new therapeutic approaches are a critical need. TP53 is mutated in the majority of SCLC cases and its loss is required in transgenic mouse models of the disease. We synthesized an array of biodegradable poly(β-amino ester) (PBAE) polymers that self-assemble with DNA and assayed for transfection efficiency in the p53-mutant H446 SCLC cell line using high-throughput methodologies. Two of the top candidates were selected for further characterization and TP53 delivery in vitro and in vivo. Nanoparticle delivery of TP53 resulted in expression of exogenous p53, induction of p21, induction of apoptosis, and accumulation of cells in sub-G1 consistent with functional p53 activity. Intratumoral injection of subcutaneous H446 xenografts with polymers carrying TP53 caused marked tumor growth inhibition. This is the first demonstration of TP53 gene therapy in SCLC using nonviral polymeric nanoparticles. This technology may have general applicability as a novel anticancer strategy based on restoration of tumor suppressor gene function. Mol Cancer Ther; 12(4); 405–15. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“ration of p53 in these models results in potent antitumor activity in a cell-type–specific manner; TP53 reexpression induces apoptosis in autochthonous lymphomas but senescence in sarcoma and hepatocellular carcinoma models (10, 11).”
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643 · cited 2×
“In transgenic SCLC models, TP53 loss is required for tumor development (13, 36).”
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Re-expression of WT p53 has potent efficacy in established p53-null lymphomas, sarcomas and hepatocellular carcinomas (10, 11, 37).”
A combinatorial polymer library approach yields insight into nonviral gene delivery
Green, J. J., Langer, R., & Anderson, D. G. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002336 · Cited by 579
Self-citationSutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · cited 1×
“cific calcitonin/calcitonin-gene related peptide promoter but not a Clara cell–specific promoter, resulted in murine SCLC, implicating pulmonary neuroendocrine cells as the putative cell of origin for SCLC (14).”
Cited by
Nanoparticles in Drug Delivery: From History to Therapeutic Applications
Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468
Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., & Shen, H. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.019 · Cited by 187
Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System
Shyam, R., Ren, Y., Lee, J., Braunstein, K. E., Mao, H.-Q., & Wong, P. C. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.15 · Cited by 58
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Metadata
- Authors
- Kamat, C. D., Shmueli, R. B., Connis, N., Rudin, C. M., Green, J. J., & Hann, C. L.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-04-01
- Volume
- 12
- Issue
- 4
- Pages
- 405-415
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2111424797
- Cited by
- 45
- References
- 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0956
- The paper
- Kamat, C. D., Shmueli, R. B., Connis, N., Rudin, C. M., Green, J. J., & Hann, C. L. (2013). Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.